title: Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients.
abstract: OBJECTIVE
  As sirolimus has been implicated in impaired wound healing, the aim of this study was to evaluate risk factors for wound complications after renal transplantation in patients treated with this drug de novo.
  
  
  METHODS
  This single center retrospective review of wound complications included 194 renal transplant recipients, all of whom received sirolimus immunosuppression in combination with reduced doses of cyclosporine (CsA) and corticosteroids de novo. A wound complication was defined as an infection, incisional hernia, or lymphocele.
  
  
  RESULTS
  The overall incidence of wound complications within the first year post-transplantation was 36% (n = 70) including infection in 12% (n = 23), lymphocele formation in 18% (n = 34), and incisional hernia in 18% (n = 34) of patients. Seventeen patients suffered more than one wound complication. A multivariate analysis showed that independent risk factors for the development of wound complications were recipients over the age of 40 yr (odds ratio 2.536, p = 0.011), subjects with body mass index (BMI) >26 (odds ratio 2.498, p = 0.027) and especially BMI >30 (odds ratio 3.738, p = 0.007), the use of thymoglobulin for induction immunosuppression (odds ratio 3.627, p = 0.002), and a cumulative dose of sirolimus of at least 35 mg by post-transplant day 4 (odds ratio 2.694, p = 0.023). African-American (odds ratio 0.139, p < 0.001) or Hispanic recipients (odds ratio 0.337, p = 0.014) were less likely to experience a wound problem than Caucasian recipients.
  
  
  CONCLUSIONS
  A number of potentially modifiable risk factors independently increase the incidence of wound complications among renal transplant recipients receiving sirolimus-based immunosuppression de novo.
authors.affiliation: Division of Immunology and Organ Transplantation, The University of Texas Health Science Center at Houston, Houston, TX, USA. richard.j.knight@uth.tmc.edu
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Knight
authors.forename: Martin
authors.initials: M
authors.lastname: Villa
authors.forename: Robert
authors.initials: R
authors.lastname: Laskey
authors.forename: Carlos
authors.initials: C
authors.lastname: Benavides
authors.forename: Linda
authors.initials: L
authors.lastname: Schoenberg
authors.forename: Maria
authors.initials: M
authors.lastname: Welsh
authors.forename: Ronald H
authors.initials: RH
authors.lastname: Kerman
authors.forename: Hemangshu
authors.initials: H
authors.lastname: Podder
authors.forename: Charles T
authors.initials: CT
authors.lastname: Van Buren
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Katz
authors.forename: Barry D
authors.initials: BD
authors.lastname: Kahan
mesh_terms: D000328:Adult; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011184:Postoperative Period; D012189:Retrospective Studies; D012307:Risk Factors; D020123:Sirolimus / Q000627:therapeutic use*; D014945:Wound Healing
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D020123:Sirolimus